Drug resistance mechanism and reversal strategy in lung cancer immunotherapy
Among all malignant tumors, lung cancer has the highest mortality and morbidity rates. The non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the most common histological subtypes. Although there are a number of internationally recognized lung cancer therapy regimens, their the...
Main Authors: | Yishi Xu, Yaqing Liu, Yi Ge, Haozhe Li, Yi Zhang, Liping Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1230824/full |
Similar Items
-
Frequency and clinical characteristics of hypophysitis and hypopituitarism in patients undergoing immunotherapy – A systematic review
by: Juliana Prudêncio Jacques, et al.
Published: (2023-02-01) -
Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)
by: Jia Li Low, et al.
Published: (2022-11-01) -
Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis
by: Isabella Sala, et al.
Published: (2024-01-01) -
Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review
by: Michele Montrone, et al.
Published: (2023-02-01) -
Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non–Small Cell Lung Cancer
by: Xuhe Liao, et al.
Published: (2022-02-01)